{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
  "queries": [
    "https://consensus.app/search/early-microbial-exposure-allergies/NMVL2m6dRq-NikiKrXPoqg/"
  ],
  "query_record_note": "Exact visible question/response retained privately in raw browser receipt.",
  "primary_comparison_count": 6,
  "primary_comparisons": [
    {
      "pmid": "11297958",
      "doi": "10.1016/S0140-6736(00)04259-8",
      "source_type": "primary study report",
      "study_group": "FINN_LGG",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Defined probiotic regimen and eczema",
      "result_comparison": "The original Finnish trial supports reduced eczema in a specified high-risk perinatal LGG regimen. This restricted positive result does not establish a universal probiotic effect, prevent every allergy, or identify protection from autoimmune disease.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/11297958/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\examinations\\original-0-20-1400.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "18762327",
      "doi": "10.1016/j.jaci.2008.07.011",
      "source_type": "primary study report",
      "study_group": "NZ_HN001_HN019",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Strain specificity challenges consistent efficacy",
      "result_comparison": "In the original randomized comparison HN001 reduced eczema while HN019 did not, and atopy comparisons were nonsignificant. Consensus's broad wording about consistently positive eczema trials must retain this strain-specific contrast.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/18762327/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\examinations\\original-0-20-1400.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "24947281",
      "doi": "10.1136/archdischild-2013-305799",
      "source_type": "primary study report",
      "study_group": "WALES_ISRCTN26287422",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Primary versus secondary endpoints",
      "result_comparison": "The original Wales trial had a null primary diagnosed-eczema comparison, with favorable secondary sensitization and atopic-eczema results. The body also shows enrollment of both familial-risk levels. The later five-year follow-up is the same parent trial, not independent replication.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/24947281/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\examinations\\original-0-20-1400.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\body-presentation-receipts\\24947281-s1-p2-9.json"
      ]
    },
    {
      "pmid": "42705251",
      "doi": "10.1016/S0140-6736(26)01443-1",
      "source_type": "primary study report",
      "study_group": "ORBEX_NCT02148796",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Missing completed clinical bacterial-lysate trial",
      "result_comparison": "Consensus omitted ORBEX and portrayed bacterial-lysate evidence as largely biomarker-based. The original 822-participant report tested a clinical primary endpoint during subsequent off-treatment observation and found no significant benefit: hazard ratio1.16, confidence interval0.82–1.64. It is a completed clinical null, not an unreported biomarker-only study.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42705251/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\examinations\\original-0-20-1400.json",
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\examinations\\original-18-19-6500.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "35930838",
      "doi": "10.1016/j.ecoenv.2022.113900",
      "source_type": "primary study report",
      "study_group": "PMID35930838",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Daycare biodiversity is an intermediate-outcome intervention",
      "result_comparison": "The original small randomized soil-enrichment study reports microbiome and immune-marker changes over14days. It does not demonstrate prevention of diagnosed allergy or autoimmunity. Consensus helped locate this original source, but the marker-to-disease boundary remains.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/35930838/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\examinations\\original-60-63-4000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "27133167",
      "doi": "10.1016/j.cell.2016.04.007",
      "source_type": "primary study report",
      "study_group": "PMID27133167",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Microbial quality and experimental system",
      "result_comparison": "The original report pairs observational infant cohorts with injected LPS experiments in NOD mice. E. coli and B. dorei signals differ. It supports exposure-specific biology rather than a general rule that more microbes protect humans; the linked correction is retained, with its detailed changes unexamined.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/27133167/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\examinations\\original-20-40-1300.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\body-presentation-receipts\\27133167-s1-p15.json"
      ]
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_remaining_priority_11_15_2026-10-11\\hygiene-hypothesis\\consensus-browser-2026-10-11.json",
      "sha256": "29b8b82df5e554ac216c28c0979968e1d2776e76f07a8408b18ac06398c8798c"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-09",
  "completed_utc": "2026-10-12T19:49:41.535787+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}